pharma · Triple Negative Breast Cancer (TNBC) · Mesothelin-Expressing Tumors · CNTX
Context Therapeutics
Context Therapeutics clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Philadelphia, USA
- Founded
- 2015
- Employees
- 26
- Programs
- 8
- Drugs
- 7
- Patents
- 3
Context Therapeutics projects
8 ClinicalTrials.gov programs sponsored by Context Therapeutics.
Context Therapeutics has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Elacestrant
Context Therapeutics
Breast Cancer
2 trials -
Extended-release Onapristone
Context Therapeutics
Refractory Endometrial Adenocarcinoma
1 trial -
Onapristone
Context Therapeutics
ER-positive Breast Cancer
1 trial -
Onapristone ER
Context Therapeutics
Granulosa Cell Ovarian Cancer
1 trial -
CT-202
Context Therapeutics
Triple Negative Breast Cancer (TNBC)
1 trial -
CT-95
Context Therapeutics
Mesothelin-Expressing Tumors
1 trial -
CTIM-76
Context Therapeutics
Platinum-resistant Ovarian Cancer
1 trial -
Letrozole
Context Therapeutics
Metastatic Breast Cancer
1 trial
Frequently asked questions
How many clinical projects does Context Therapeutics have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.